Abevmy Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

abevmy

biosimilar collaborations ireland limited - bevacizumabas - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antinavikiniai vaistai - abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. daugiau informacijos apie žmogaus epidermio augimo faktoriaus receptorių 2 (her2) būklę rasite 5 skyriuje. abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with abevmy in combination with capecitabine. daugiau informacijos apie her2 statusą rasite 5 skyriuje. abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics [figo] stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Pemetrexed Mylan Pharma Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

pemetrexed mylan pharma

mylan s.a.s. - pemetreksedas - milteliai infuzinio tirpalo koncentratui - 500 mg; 100 mg; 1000 mg - pemetrexed

Pemetrexed Zentiva [Pemetrexed Alvogen] Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

pemetrexed zentiva [pemetrexed alvogen]

zentiva k.s. - pemetreksedas - milteliai infuzinio tirpalo koncentratui - 1000 mg; 100 mg; 500 mg - pemetrexed

Pemetrexed Norameda Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

pemetrexed norameda

norameda, uab - pemetreksedas - milteliai infuzinio tirpalo koncentratui - 100 mg; 500 mg - pemetrexed

Pemetrexed PharmaSwiss Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

pemetrexed pharmaswiss

pharmaswiss Česká republika s.r.o. - pemetreksedas - milteliai infuzinio tirpalo koncentratui - 500 mg; 100 mg - pemetrexed

Pemetrexed Teva Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

pemetrexed teva

teva b.v. - pemetreksedas - milteliai infuzinio tirpalo koncentratui - 500 mg - pemetrexed

Pemetrexed Ebewe Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

pemetrexed ebewe

sandoz d.d. - pemetreksedas - koncentratas infuziniam tirpalui - 25 mg/ml - pemetrexed

Docetaxel Hospira Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

docetaxel hospira

hospira uk limited - docetakselis - koncentratas infuziniam tirpalui - 10 mg/ml - docetaxel

Paclitaxel Accord Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

paclitaxel accord

accord healthcare b.v. - paklitakselis - koncentratas infuziniam tirpalui - 6 mg/ml - paclitaxel

Camitotic Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

camitotic

teva b.v. - docetakselis - koncentratas infuziniam tirpalui - 20 mg/ml - docetaxel